AQR Capital Management
BCAX

AQR Capital Management’s Bicara Therapeutics BCAX Stock Holding History

AQR Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$262K Buy
+13,186
New +$227K ﹤0.01% 3474
2025
Q2 		– Sell
-19,034
Closed -$248K – 3413
2025
Q1 		$248K Buy
+19,034
New +$253K ﹤0.01% 2776

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

AQR Capital Management's BCAX Position: Q1 2026 in Review

AQR Capital Management opened a new position in Bicara Therapeutics (BCAX) in Q1 2026: 13,186 shares worth $262K. The stake represents ﹤0.01% of the portfolio and ranks #3474 among its holdings. This is a return to the name: AQR Capital Management previously reported a position in BCAX as recently as Q1 2025.

AQR Capital Management first reported a position in BCAX in Q1 2025 and has held it in 2 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • AQR Capital Management held 13,186 shares of Bicara Therapeutics worth $262K as of Q1 2026.
  • Bicara Therapeutics was a new AQR Capital Management position in Q1 2026.
  • Bicara Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3474 holding.
  • AQR Capital Management first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.